| Section Editors | |
| Contributing Authors | |
| Preface | |
| Acknowledgments | |
| Overview | p. 1 |
| The History of Ocular Pharmacology | p. 3 |
| Pharmacodynamics: Drug-Receptor Interactions | p. 9 |
| Drug Reactions Not Mediated via Receptors | p. 35 |
| Cholinergics | p. 41 |
| Eicosanoid Receptors in Ocular Tissues | p. 51 |
| Steroids in Ocular Therapy | p. 61 |
| Adrenergic Pharmacology of the Anterior Segment | p. 75 |
| Immunosuppressive Therapy for Uveitis | p. 95 |
| Ocular Pharmacokinetics | p. 119 |
| Basic Considerations of Ocular Drug-Delivery Systems | p. 139 |
| Development of New Drugs for Ophthalmology | p. 151 |
| Ethical Issues in Ophthalmic Research | p. 165 |
| The Ophthalmologist as Clinical Investigator | p. 171 |
| Introduction to Toxicology | p. 179 |
| Effect of Disease on Drug Disposition | p. 187 |
| Effect of Age on Drug Disposition | p. 197 |
| Effect of Pregnancy on Drug Disposition | p. 205 |
| Overview | p. 217 |
| Definitions and Classification of Glaucoma | p. 219 |
| Direct, Indirect, and Dual-Action Parasympathetic Drugs | p. 221 |
| Epinephrine and Dipivefrin | p. 239 |
| Alpha-2 Agonists in Glaucoma Therapy | p. 247 |
| Thymoxamine (Alpha-Adrenergic Antagonist) | p. 255 |
| Beta-blockers | p. 261 |
| Oral Carbonic Anhydrase Inhibitors | p. 277 |
| Topical Carbonic Anhydrase Inhibitors | p. 287 |
| Hyperosmotic Agents | p. 291 |
| Antifibrosis Agents: Pharmacologic Inhibition of Wound Healing | p. 297 |
| Prostaglandins and Prostaglandin Analogues | p. 315 |
| Future Role of Neuroprotective Agents in Glaucoma | p. 329 |
| Medical Trabeculocanulotomy | p. 341 |
| Physiologic Aspects of Glaucoma and Its Current and Future Management | p. 347 |
| Overview | p. 361 |
| Antibiotics and Antifungals | p. 363 |
| Antivirals in the Treatment of Retinal Diseases | p. 387 |
| Pharmacologic Therapy for Cystoid Macular Edema | p. 409 |
| Proliferative Vitreoretinopathy: Biology and Pharmacology | p. 417 |
| Drugs Affecting the Coagulation/Fibrinolysis Pathways | p. 429 |
| Ocular Pharmacology of Diabetic Retinopathy | p. 443 |
| Medical Therapy for Macular Degeneration | p. 447 |
| Angiogenesis and Growth Factors | p. 455 |
| Overview | p. 471 |
| Penicillins and Cephalosporins | p. 473 |
| Antiparasitic Agents | p. 493 |
| The Tetracyclines | p. 507 |
| Erythromycin, Clarithromycin, and Azithromycin | p. 515 |
| Chloramphenicol | p. 525 |
| Aminoglycosides in Ophthalmology | p. 531 |
| Fluoroquinolones | p. 537 |
| Peptide Antibiotics: Vancomycin, Bacitracin, and Polymyxin B | p. 549 |
| Rifampin | p. 559 |
| Amebic Disease of the Eye | p. 565 |
| Antivirals | p. 575 |
| Pharmacotherapy of Fungus Infections of the Eye | p. 587 |
| Antiallergic Therapies | p. 609 |
| Intraocular Irrigating Solutions | p. 635 |
| Surgical Viscoelastic Substances | p. 655 |
| Antiseptics and Disinfectants | p. 661 |
| Mitomycin Treatment of Corneal Disease | p. 667 |
| Cyanoacrylate Tissue Adhesives | p. 671 |
| Future Developments in Corneal Therapy: Growth Factors | p. 675 |
| Overview | p. 681 |
| Pharmacology of Medical Therapy for Uveitis | p. 683 |
| Mydriatic and Cycloplegic Agents | p. 703 |
| Nonsteroidal Antiinflammatory Drugs | p. 713 |
| Immunosuppressive Chemotherapy | p. 723 |
| Overview | p. 763 |
| Anesthetic and Perianesthetic Medications | p. 765 |
| Anesthetic Considerations for Ophthalmic Surgery | p. 771 |
| Overview | p. 781 |
| Topical Ophthalmic Preparations Used for Infants and Children | p. 783 |
| Cycloplegic Agents | p. 787 |
| Topical and Local Anesthetic Agents | p. 791 |
| Antiglaucoma Medications | p. 795 |
| Ocular Antiinflammatory Agents | p. 801 |
| Overview | p. 805 |
| Mydriatic and Cycloplegic Drugs | p. 807 |
| Drugs for the Diagnosis of Pupillary Disorders | p. 827 |
| Drugs for the Diagnosis and Treatment of Myasthenia Gravis | p. 837 |
| Sodium Fluorescein and Other Tissue Dyes | p. 849 |
| Subject Index | p. 865 |
| Table of Contents provided by Blackwell. All Rights Reserved. |